PMID- 35696192
OWN - NLM
STAT- MEDLINE
DCOM- 20220708
LR  - 20220808
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 97
IP  - 8
DP  - 2022 Aug
TI  - Human leukocyte antigen-haploidentical transplantation for relapsed/refractory 
      acute myeloid leukemia: Better leukemia-free survival with bone marrow than with 
      peripheral blood stem cells in patients >/=55 years of age.
PG  - 1065-1074
LID - 10.1002/ajh.26627 [doi]
AB  - The best stem cell source for T-cell replete human leukocyte antigen 
      (HLA)-haploidentical transplantation with post-transplant cyclophosphamide (PTCy) 
      remains to be determined. In this European Society for Blood and Marrow 
      Transplantation retrospective study, we analyzed the impact of stem cell source 
      on leukemia-free survival (LFS) in adult patients with primary refractory or 
      relapsed acute myeloid leukemia (AML) given grafts from HLA-haploidentical donors 
      with PTCy as graft-versus-host disease (GVHD) prophylaxis. A total of 668 
      patients (249 bone marrow [BM] and 419 peripheral blood stem cells [PBSC] 
      recipients) met the inclusion criteria. The use of PBSC was associated with a 
      higher incidence of grade II-IV (HR = 1.59, p = .029) and grade III-IV 
      (HR = 2.08, p = .013) acute GVHD. There was a statistical interaction between 
      patient age and the impact of stem cell source for LFS (p < .01). In multivariate 
      Cox models, among patients <55 years, the use of PBSC versus BM resulted in 
      comparable LFS (HR = 0.82, p = .2). In contrast, in patients >/=55 years of age, 
      the use of PBSC versus BM was associated with higher non-relapse mortality (NRM) 
      (HR = 1.7, p = .01), lower LFS (HR = 1.37, p = .026) and lower overall survival 
      (HR = 1.33, p = .044). In conclusions, our data suggest that in patients 
      >/=55 years of age with active AML at HLA-haploidentical transplantation, the use 
      of BM instead of PBSC as stem cell source results in lower NRM and better LFS. In 
      contrast among younger patients, the use of PBSC results in at least a comparable 
      LFS.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Baron, Frederic
AU  - Baron F
AUID- ORCID: 0000-0002-2944-3812
AD  - Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liege, Liege, 
      Belgium.
FAU - Labopin, Myriam
AU  - Labopin M
AD  - EBMT Paris Study Office/CEREST-TC, Paris, France.
AD  - Service d'Hematologie Clinique, Hopital Saint-Antoine, AP-HP, Paris, France.
AD  - INSERM UMRs 938, Paris, France.
AD  - Sorbonne University, Paris, France.
FAU - Tischer, Johanna
AU  - Tischer J
AD  - Campus Grosshadern, LMU, Department of Internal Medicine III, University Hospital 
      of Munich, Munich, Germany.
FAU - Ciceri, Fabio
AU  - Ciceri F
AD  - IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.
FAU - Raiola, Anna Maria
AU  - Raiola AM
AD  - IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
FAU - Blaise, Didier
AU  - Blaise D
AD  - Programme de Transplantation&Therapie Cellulaire, Departement d'hematologie 
      Centre de Recherche en Cancerologie de Marseille, Aix-Marseille University, 
      Institut Paoli Calmettes, Marseille, France.
FAU - Sica, Simona
AU  - Sica S
AD  - Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, 
      Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
AD  - Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, 
      Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Vydra, Jan
AU  - Vydra J
AD  - Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
FAU - Fanin, Renato
AU  - Fanin R
AD  - Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy.
FAU - Stolzel, Friedrich
AU  - Stolzel F
AD  - University Hospital Dresden, Medical Clinic I, TU Dresden, Dresden, Germany.
FAU - Busca, Alessandro
AU  - Busca A
AD  - SSCVD Trapianto di Cellule Staminali, AOU Citta della Salute e della Scienza di 
      Torino, Torino, Italy.
FAU - Diez-Martin, Jose Luis
AU  - Diez-Martin JL
AD  - Head of Hematology Department, Hospital G U Gregorio Maranon, Instituto de 
      Investigacion Sanitaria Gregorio Maranon, Medicine Dpt. UCM, Madrid, Spain.
FAU - Koc, Yener
AU  - Koc Y
AD  - Bone Marrow Transplant Unit, Medicana International Hospital Istanbul, Istanbul, 
      Turkey.
FAU - Nagler, Arnon
AU  - Nagler A
AUID- ORCID: 0000-0002-0763-1265
AD  - Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical 
      Center, Ramat-Gan, Israel.
FAU - Mohty, Mohamad
AU  - Mohty M
AD  - EBMT Paris Study Office/CEREST-TC, Paris, France.
AD  - Service d'Hematologie Clinique, Hopital Saint-Antoine, AP-HP, Paris, France.
AD  - INSERM UMRs 938, Paris, France.
AD  - Sorbonne University, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220624
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (HLA Antigens)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Bone Marrow
MH  - Bone Marrow Transplantation/adverse effects
MH  - Cyclophosphamide/therapeutic use
MH  - *Graft vs Host Disease/etiology/prevention & control
MH  - HLA Antigens/genetics
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - *Peripheral Blood Stem Cell Transplantation/adverse effects
MH  - *Peripheral Blood Stem Cells
MH  - Recurrence
MH  - Retrospective Studies
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Haploidentical/adverse effects
EDAT- 2022/06/14 06:00
MHDA- 2022/07/09 06:00
CRDT- 2022/06/13 11:34
PHST- 2022/05/24 00:00 [revised]
PHST- 2022/03/29 00:00 [received]
PHST- 2022/06/01 00:00 [accepted]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/07/09 06:00 [medline]
PHST- 2022/06/13 11:34 [entrez]
AID - 10.1002/ajh.26627 [doi]
PST - ppublish
SO  - Am J Hematol. 2022 Aug;97(8):1065-1074. doi: 10.1002/ajh.26627. Epub 2022 Jun 24.